WAT - Earnings call transcript Q4 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to the Waters Corporation Fourth Quarter 2019 Financial Results Conference Call. All participants are in a listen-only mode until the question-and-answer session of the conference call. This conference call is being recorded. If anyone has any objections, please disconnect at this time.

It is now my pleasure to turn the call over to Mr. Investor of Head Brokmeier, Relations. Bryan sir. Please go ahead,

Bryan Brokmeier

welcome Thank Corporation’s Waters and call. you, Good morning, operator. to fourth the everyone, quarter conference earnings

Before cover will we language. begin, the cautionary I

various this financial for future of the the full regarding the we and we During possible events particular, performance conference year In first provide course regarding future quarter of will the XXXX. company make will forward-looking company. future statements or of call, guidance results

expectations present that such statements are or We may actual caution you results our events that all only and differ materially.

some in detailed discussion differ the a cautionary expectations, that included under For contingencies and Part our Risk Factors, Report Annual X-K. could from our of included see release language to of performance our caption, X risks year factors risks on in actual Form XX-K and XXXX, the the the present the for this cause fiscal and morning’s in significantly press XX, ended December

We its is not further scheduled release caution you webcasts webcast update conference next our required law. for earnings calls and or XX, or quarterly April The except predictions any call release regularly earnings by and planned does during to intend otherwise projections, as currently that XXXX. the company of

available attached will are certain the to financial Reconciliations company’s of our measures During release be the on referring today’s measures non-GAAP earnings call, this non-GAAP comparable website. directly to we to financial and morning GAAP measures. the issued most

titled GAAP release. may Adjusted the to of those in impact included outlined our In as our the press operations, Reconciliation to morning’s results, non-GAAP items discussions of of exclude which Financials of schedule refer Non-GAAP this results such we in

comparison fourth references decreasing are otherwise, of year to increasing or fiscal stated to results XXXX. Unless the quarter quarterly in

basis. revenue given comparable currency growth In revenue stated today’s rates, given are a all year-over-year on constant ranges on call, otherwise, including growth addition, unless

Chief Officer. Now, the O'Connell, Chris? Waters’ I’d and Chris call turn to Chairman Executive like to over

Christopher O'Connell

Waters’ for you with morning, me Thanks, morning’s Brokmeier, everyone. joining this Bryan, joining Financial Thank on Bryan Buck, Along us and good Chief Sherry Officer. today. is call

overview and financial fourth our full summarize some quarter call, today's in will XXXX quarter our our review detail broader outlook. I'll results, provide an first well During and year XXXX operating of as then commentary results on business. as our Sherry full-year financial and

then will your to the up We open phone take lines questions.

XXXX, reviewing encouraging grew X% adjusted those earnings our market fourth to particularly The progress revenue products. share with we quarter mixed throughout impact similar with Briefly per key as grew our results also for operating growth positive on out played conditions quarter, but the fourth generally initiatives, new XX%. expected, experienced we and of the

capital In continued pharma largely the was biomedical and in by our offset our research industrial in spending product small molecule in markets, growth softness and molecule pharmaceutical applications. China new by large offerings conditions driven market applications quarter

were we at set Looking in per full Macro conditions and capital throughout XXXX cautious the market in purchasing markets and X%. than the end variable grew more of serve entering XXXX in factors willing earnings adjusted key share more to to year a total, led had delay Customers X% we year. spending. revenue expected more grew their

impacted the most where I'd were areas dynamic. to by this three like we review

and policy pharmaceutical China First, the changes affected government food in markets.

company. As key a global a priority represents to reminder, growth China be our continues of and revenue XX% the for

as with within coming food industry from in our global portfolio the a mix our as unique is well higher testing. pharma business concentration of business Our and China within

in the market the to academic steady, cautious, expect double-digit industrial X by stabilization were year-over-year revenues conditions view and but market. stable year to China XXXX flat XX moderate relative on of the initial food following China end In spending, growth In XXXX XXXX into pharma years. prior in our spending coming is and driven

Therefore, That Coronavirus are have closely is in rapidly the our what evolving situation said, business. understand early will impact impact on this XXXX and we guidance. too it's no outbreak to monitoring included our

As and customers appropriate priority and are employee top caution our and families, employees, terms travel in our the of we and their our is health always, of taking safety activities.

market molecule Waters molecule our down Second, pharmaceutical environment. where LC and market. the the focus applications, modestly has global business in overall growth In with capability, a was line XXXX for has been in small small unique slower pharmaceutical

XXXX. to ahead assumptions stable Looking conditions our to market XXXX assume relative

world, Meanwhile increasing all market, the secular steadily we the drivers of safety medications growth remain well rises markets. to the increasing therapeutic including small molecule and volumes as quality patient access underlying confident LC in as prescription around in as requirements

continue demands normalizes. our when well-positioned are invest benefit advancing instrument in LC and to to We portfolio

And was offset and as industrial in governmental academic market strength. third, Europe XXXX flat headwinds

in Looking improvement stabilization help within encouraged supports we're that around Brexit to This fourth the quarter and ahead stabilize XXXX. confidence macroenvironment. region our clarity could contributed in modestly conditions European the better our

growth we on of organic excited core new about in Market significant XXXX. during focused are strategy sharply and dynamics remain our launches the meaningful aside, uptick innovation product

activities new our to by in particularly the products We encouraged date increasing QX. market development and pleased are with contribution of

the BioAccord, SYNAPT XS that this and contribution contributed quarter product and will ramp in Cyclic IMS, our all spectrometers, the to two meaningfully our more quad to mass notably, new we XXXX. growth new Most tandem continue in expect

at roadmap new R&D more in technology a that excited product are productivity and front and but the future. cadence adorable we a cycle, our product not only improvement sustainable new We of therefore about the remain end into also very major believe

closer our the flat difficult in were was applications sales a review broadly decline ago. category clinical pharmaceutical as attributable quarter. the our as market India at in Taking offset sales pharmaceutical defined to a softness China the Geographic business at into well strength which partly by level, comparable and for year is starting a with a to business look of our corporate in Europe quarter the categories

market investments small in by pharmaceutical molecule quarter. category this LC, Conversely, and softer remained revenue levels focused applications large and flat with mass remained our than the The molecule robust, market global in the performance spectrometers it within our across historical for global supported chemistries.

X%. category For year were sales the full our up pharmaceutical

material worldwide quarter which category during in science, and strength includes down by the markets were industrial our in QX materials environmental up characterization. with markets to offset Sales testing in weakness the food X% food

category year the sales down X%. worldwide our full For industrial were

to technologies our in research Sales and were particularly of and by academic and biomedical new quarter, the fourth categories driven XX% the our pharmaceutical U.S. categories, in the Europe. the governmental up impact serving

academic our governmental year sales were up full category the For X%. and

I at the performance geography corporate our Next review sales will by level.

the difficult by comp, declined the was our food stabilization Asia, markets. terms partially on in flat fourth as modestly declined China quarter in region a offset in largest revenue, X% of quarter. pharmaceutical in growth

the pharmaceutical X specifically the played of Looking X at process, to the we round underway. the market, as China out expected, referred [ph], now the program previously plus second third and is generic GPO round as

are pragmatic to continue see we process benefits this scale. local maintaining to tenders and requirements a of the stringent some those notably quality program's through and Our big and tone pharma companies increasingly due their win customers customers, multinationals

generic customer We see also bolstering to we are the confidence as China, seeing chemistry which supports this our will process for GPO continue offerings our that demand time. volume rising in prescription base, strong increasing instrument over expect we demand from

partially in continuing by driven food was the market, growth solid India, pharmaceutical the recovery by offset softness. In

For India, in China while the Japan was and by flat. Korea, full year, Asia growth grew X%, solid driven

quarter, the as in research declined in revenue in molecule molecule and part food driven U.S., fourth was the to was material flat and fourth in offset both in the strength large small ongoing pharma, in Overall, Brazil. quarter the to pharma, in and clinical Latin X% Americas due Mexico by instability expected Turning weakness applications. biomedical weakness America, by political science the

U.S. X% total while For revenue the full was year the flat. grew Americas

industrial. solid budget customers grew spending and academic and by in instruments a customers. result demand for the offset We saw strength our strength mass particular by and of a sales from governmental, Europe, continued both certain pharma year-end in decline new In modest partially academic pharmaceutical spectrometers in quarter, X% large in

were sales full in Europe flat. year, the For

X% that Waters instruments within TA and for line X% LC LC Finally, I Waters can moderately in review product our LC we and growth year. the patterns trends instrument to improving spending our support Market broader earlier. leverage are confident spoke base LC portfolio strong sales aside, recover. product we declined dynamics market with customer and about will installed the declined expanding when dynamics consistent brands. quarter that branded we

key in fourth market meaningful growth a contributions Cyclic mass reason demand and driven the solid quarter In in spectrometers, by portfolio the XS in progressed producing and furthering and multiyear Momentum geographies, as activities across governmental academic and of continues growth. QX were well the our business. development fourth well to ramp. a quarter as for strong rich our a BioAccord made was SYNAPT new strong new the food complements IMS for The revenue as to build all global products,

two and Global XS SelectScience's best award the Frost and portfolio already XXXX addition we for Scientist's see we XXXX, applied Sullivan's us our products, the for to New have including SYNAPT markets. major the Lastly, food in development Choice reception the To new one & for BioAccord, new and global of received from positioning for overall awards Innovation two and Award. quads to product our Product attest Award tandem benefit enthusiastic new any strengthened of the pickup the discovery drug

strength service UPLC quarter X% a and for and We recurring grew Waters year. application of Chemistry portfolio, columns, our solid HPLC branded X% the chemistry bioseparations was driven across including our columns by and revenues, columns. combination growth the which business. pharmaceutical saw reflect precision in chemistries, kits,

declined X% which largely chemicals based by and XX% and system down up reduced geographies. TA Turning levels instrument product weakness was the sales customers, spending with The line, to to and fourth service polymer due broad TA quarter our largest portfolio across our our sales sales instrument in was X%.

sales XXXX, Despite full challenging growth return we TA conditions the to declined year, TA confidence portfolio, strong have XXXX. X%. instruments' X% in our product and sales TA market sales with line service we and to in faced and in instrument up down our team expect product For X% system the

in XXXX, environment throughout Returning than on steadfastly more we the our global focused expected. on in the our challenges year macroeconomic capital we To creation purchasing the model. who remain impacted to big were recap customers cautious value five-point picture, their executing

strategy aim a capital by maintaining by, X) and value seeking channel, have holding shareholder operational and growth create innovation; and structurally operating for driven innovation, X) organic a consistently X) position improvement markets; in culture in attractive executing leading focused discipline; operations: communicated, we we with team. specialty opportunities to oriented X) continuous performance As X) a management

Our long-term to deliver goal growth. strong remains sustainable

management, portfolio the investments along highlighted meaningful markets, past several the by productivity. resulting which selection approach We disciplined as innovation. R&D of is durability a over years, well the in that R&D growth our strategy as to consistent more project confident opportunity and in corporate our in are in is improvements end Accelerated with

to to by innovation of Looking actively further seek we XXXX, our to products. and M&A. Furthermore, realize launched we more expect deploying growth capital ahead purposeful to benefit our organic recently supplement

Over the investment we strengthened past two internal a years and capabilities robust built pipeline. acquisition and minority our have

technology announced our material and impact and advanced science workflows that Last markets. broadening of acquisition life customers' pharmaceuticals, portfolio Alliance the to our month sciences include positively we Andrew will robotics across software

Sherry With to XXXX for for over that, I'd Sherry? outlook QX like XXXX. and our review and to a financials of pass call our the Buck

Sherry Buck

as and approximately sales sales sales constant of million, translation growth we increase Currency reported. currency. X% good fourth net decreased the by Chris you, morning In of an approximately recorded Thank in everyone. in quarter resulting flat X% $XXX

X% full about year the in of decreased currency grew For a X% year approximately growth full sales on declined X%, translation, basis. sales sales a resulting approximately before by reported which

into grew quarter, category sales academic flat, sales our category industrial the pharmaceutical our and XX%. our were were into X%, governmental down category In

For industrial X%. the market and grew the our full year, X%, and category category governmental was declined our category X%, pharmaceutical academic market up

represents chemistry Looking declined a quarter, X% recurring products and grew X%. revenue precision while product line growth, service at which instrument sales revenue in of the our combination

grew year groups full the revenue X%. For while sales X% product declined recurring for instrument

revenue sales calendar sales. slight the last day which were one a quarter, in resulted by additional in service in increase recurring quarter, As we impacted noted

day there fourth of the the days and calendar in is less one in two additional ahead, first Looking calendar compared to quarter XXXX quarter XXXX.

while were product sales TA to were and X% sales Combined LC/MS X%. quarter down and products instrument sales products fourth down platform Breaking X% Waters further, TA. related of sales grew LC services services down and for branded branded sales instrument XX% and declined

flat were our X%. fourth at up sales in growth with geographically, Asia X% Looking were Americas the with flat quarter rates down U.S. in and Sales declining China European X%. sales in were

X% Americas the Sales For China U.S. were the and X% with year up Asia the in sales Europe sales with were flat. sales up flat flat. were

to I'd was performance year. of fourth the financial margin XX.X% like our prior for to XXXX. quarter on Gross full in versus full was as was the compared Now driven rates, the to a lower On margin the compared gross the The gross and non-GAAP year comment quarter mix. quarter year fourth prior basis absorption the quarter relative prior XX% both margin the year in to year in year. by cost XX.X% XX% fixed foreign exchange and and lower

expenses expenses versus the lower the quarter our and controls P&L, down tax operating the result effective year. currency were throughout This year year the constant and X% fourth quarter of XX% in on X% operating Moving quarter lower was about In prior a rate in spending disciplined the variable lower XX% the for quarter. basis. was a

and flat discrete net year. the was rate Net in prior $X about from effective our mix is position expectation million, of quarter. of year. over as operating our tax year debt course anticipated a an prior XX%, jurisdictions of the result $XX versus is the against items expense to about profits a shifted the our interest rate we tax the which million year as the of increase For tax in the full lower The was

shares, Our fourth of our year. effect million a a or count in repurchase shares than the average share program. This quarter is last XX% million came in of share count XX XX.X at ongoing about share net lower approximately of reduction

of $X.XX XX%. quarter per basis, $X.XX in a to for fully Our diluted compared year, On $X.XX earnings increase our fully year. increased share last per last GAAP earnings an the non-GAAP share to increased to $X.XX comparison diluted to fourth

versus For were the share fully year. full diluted per $X.XX last up year our non-GAAP earnings $X.XX share per X% to

ongoing non-GAAP diluted per $X.XX result fully this of the a share earnings the earnings reconciliation earnings our of the On program. GAAP our the in to GAAP full-year share expenses Overall, and share issued to lower quarter is attached repurchase year growth for A was versus the $X.XX release basis non-GAAP per morning. XXXX. were press and

flow, as and the $XX cash the expenditures this of free chemistry Taunton million Excluded to operations activities. excluding $XXX deployment, flow the capital balance Turning from came capital free after full quarter like cash dollar each flow our summarize in converted free at funding We cash to fourth our capital and In free special quarter fourth fourth year. of to investment from cash cash quarter define and cash $X.XX sheet, less resulted our into sales results $XX of in expenditures. I'd million related XXXX new was flow flow in facility. for In free and $X.XX items.

and capital update Now areas; three related fourth of return to deployment, like I'd which growth, capital shareholders. an on activities into to balance our categorized quarter to for strength and investing provide sheet flexibility, we

our stock $XXX the shareholders, along in a $X.X cash of our cash with free at we $XXX This short-term of about debt million net resulted of quarter. on common activities, quarter. terms These balance returning end million for the our debt resulted to of capital investments of In of in $X.X position end net and billion EBITDA of to the capital repurchased million of billion the debt fourth shares at X.X and year. allocation a X.X flow times the in ratio and sheet

the priorities X.X structure in of capital net will context to working and towards times EBITDA. continue a capital we ahead, remain to approximately committed Looking deploying our debt three of

full quarter. million during approximately reflects $XXX of $XXX guidance repurchases of shares million our result, the a As about first share year with

updates and evaluate as the repurchase will appropriate. the share our of course Over provide year program we

new days of by the capital, quarter by our contingency year. to up to million products. year this compared accounts the both, quarter, ramp continued prior to receivable to comparison the came in last support related increased to of sales inventories build driven outstanding Brexit at fourth In slightly quarter the Turning planning inventory planned XX days, working in quarter, $XX and

pharma we our on benefits product growth, broader guidance. Chris some expect year year like context returning we points As ahead, new to our the from stable sales recent XXXX outbreak support full in These To Coronavirus constant but guidance forward TA several XXXX instruments guidance. the from note year in into earlier, dynamics increasing and mentioned impacts growth LC of introductions, have our market, currency provide stability to summarize the I'd China, to not been conditions look potential for full factored X% X%. to that that

Gross operating range assumed is and based growth XXXX rates, Accordingly, controls. XX%, be to in to XX% guidance look of to neutral current XX.X%. normalization margin sales and be for XXXX full to expect expenses, combination the of currency a investment, At Every we growth. investments, growth, profitability. year we of expected disciplined year variable approximately translation of is a margins approximately on expense balance to

Andrew line, Moving net of full $XX XX% of approximately tax of of diluted effective X together $X.XX modest below XX%, are, for growth key negative range a the of currency rate per XX.X non-GAAP million an income diluted assumptions full outstanding, other $X.XX, on on full basis, in million operating XXXX which earnings the and this shares earnings share share year for year percentage to guidance lastly year assumes approximately average share $XX full count interest to from and year million, Alliance. point. impact acquisition a dilution all are of projected expense Rolling a fully

is first than quarter growth growth to today's point. the we flat Looking less expect currency sales at sales At rate by of X%. currency percentage expected decrease translation quarter X XXXX, be first to constant to

currency $X.XX. to growth At is earnings be non-GAAP point. the earnings on of current share to to rates, is diluted percentage fully X per expected estimated quarter share quarter negative approximately $X.XX first the First impact range in per be

comments. make few a Chris? summary Chris will now

Christopher O'Connell

Sherry. you, thank Great,

played fourth with macro headwinds, in newly throughout of largely our said, saw our to released saw what encouraging XXXX. of an uptick similar we as fourth the summary, quarter. quarter In a sales expected That we in out continuation we products

As investments as and of to profitability support we to growth look XXXX, industry-leading our return strategy is balancing to our as to our shareholders. capital consistent and deliver improving right on execution well a with the growth, innovation focus long-term

the we will now begin that, With session. question-and-answer

Investor the yourself are please everyone's follow-up. and Relations please we able have one limit team one additional you the after And question always questions, questions, to to not As Waters get to if call. Operator? contact

Operator

The Kumar, Evercore from first Vijay coming ISI. question is

open. Your line is

Vijay Kumar

you Chris, one on you I on the weakness any to on, assuming in how assuming is guys, that thoughts one markets all taking please. out? end thanks question. coming segment especially for Are have pharma, pharma, my of XXXX? we that guidance, Industrial, back? that some just going And shake follow-up for America at you right, saw did of is I appreciate the TA customers, the know the are North Hey markets some on you industrial, what colors end look when then decline.

Christopher O'Connell

Vijay. Sure, thanks for the question,

conditions geographic As you the by categories. molecule particularly business we have considerations some XXXX mix variable of we a in mix know have had the LC some of part pharma certainly in small and in of industrial the throughout market the set impacted we was and large really China,

just XXXX, is XXXX. conditions a our turn we starting page of the really carry-over market from As to point

XX% out, market we and of our looking not we which With molecule change small of overall regard a is in large softness robust XX% Within opportunities our moderate of continued include an the performance continued at this to the a mix about - in and pharma both and pharma, point and the point. We're clear each as the of category why mix, the risks. is have that's you acceleration we're molecule assumptions pharma geography assuming to in see view the until market, balance market, market. kind which our

and From TA, standpoint, saw the in an and industrial companies. biggest you chemicals large were we impacts referenced polymer

particularly look have industrial say were TA, ever are really polymers are global when that. down, chemicals new up quarter. and they and you to If fourth in companies, top the year the Interestingly XX TA account last very the than try at those actually within companies our soft year that, we but we in to the through enough large it's to overcome added make more accounts for challenging big

and also as polymers say phenomenon that I Waters support would branded in customers well and saw we as do industrial we that exact through on And our we in saw products side, same chemicals. TA same the the those Waters

we're So not conditions. again, a we assuming our assumption is, major but are assuming there stable rebound,

thought And just it the as and into so, part XXXX of until to we 'XX assume was will in go of continuation conditions the a see we some early different along. we conditions we prudent we saw some of update where

Vijay Kumar

dynamic the you're Sherry, margin here, That's this the step saw And of 'XX product here. assuming guidance gross rate tax looks it some helpful. would EPS to a step up? just activities down in curious, we a launches the and margins that like continuation in the new just and support commercial the on maybe step-up I'm is of is or why Thank you.

Sherry Buck

Yes.

The cover So FX. margins XX% buried operating growth. try gross margins a margin we've really our range, biggest in you've really plus back leverage we of gross gross and guidance, I'd of our The Vijay, mid is our growth. to got I'll so about at couple higher we our single-digit that overall volume say levers function our the two lower questions We a had look bit, down on and And topline a are had little in years gross all. when margin them Peeling think margins. there margin. gross in

So a of I'd function guide. is margin line say the gross top really our

our really a similarly into expenses to trying XXXX, And our margin operating balance and operating with strike investment we're and between profitability. growth, coming

also have costs we variable of into headwind for we're with so capabilities. and to some in our invest some and XXXX R&D commercial Alliance. expenses And normalization continuing coming But Andrew

of for our XX% inputs operating So guide margin. that's our

was in rate quarter mix our as in rate we the Moving in and quarter we're to the on expecting of about, tax due were jurisdictions, items our to fourth some not than favorable profits asked expecting. you discrete That as tax XXXX. repeat that the the tax that to well ended more we

So for after the to range really out of to reform, we tax of XX% our XX%. business came at rate that in we're looking tax be

Vijay Kumar

All right, thanks guys.

Operator

The is from Tycho Peterson, question next coming JPMorgan.

line open. is Your

Tycho Peterson

Chris, couple maybe conference ago, If start go longer-term you've highlighting think But a I products, got I target. with you did of I if highlight comps. I'll Thanks. single maybe that's about and what our and the the mid were In back-to-mid back this if you talk drivers takes how digits. weeks easy single you to from guide. your know to Can here, back is you just about of view you're product it expecting business declining much digit other portfolio year? new get launches? out words, new these some the products new this

there And but cost, also gross pricing margins, fixed I any called know there? was in pricing out as sensitivity there is FX then on you any well? headwind and

Christopher O'Connell

over secular market competitive appreciate we normal market underlying Sure, conditions on demand about market our We The Yes, of your our thanks, and the drivers, underlying more scenario strategy our and fundamentals a long-range and really a term under what exactly mid to support of and I at basis. confidence strong. unique long-term single-digit belief were kind talking in conferences, the long the Tycho. that's underlying the question. think is are the target - position continue would absolutely. over time dynamics are fundamentals our

that of and that not I be starting faced our the to we markets we the is the particularly outlook in clearly, between exposed a saw. is we're assume of - difference those where change immediate carryover before that function simply near-term to more the point of the mentioned that from that challenges conditions And overnight as that and a some

out molecule the to growth segment, plus, back to into terms up don't in notably a China take the market a key general growth, of really in to and it would mid-single returning certainly markets. segments, demand of in industrial reasonable digit so, of the of stabilization have And markets. small normalization get what We get the pharma industrial couple within conditions huge the it's

the out markets growth of business. We historic industrial have more to of norm then get and the in a modest pharma of terms

the see really has with that and the continued to robust As remain And perking into it's small about large up. in this that building, market the through we back for space certainly but so space, of period, pent-up stay we whole we'll I before, until space mentioned pharma Waters molecule for do cautious. the and to market it demand deferred investment molecule come some see continue

it pricing, in terms As assumptions. in unusual to is nothing pricing relates there of our

We have seen quite side. the stable pricing instrument on

We margin continue deterioration about through all and the revenue small the gross talked despite seen our margin. things, put we've recurring other on in these increases in Sherry to trade dynamic FX no side. And

So anyway that. I'd that's how summarize all of

Sherry Buck

year-over-year I'd and gross the was that remainder quarter, lower to gross margin add in absorption bit. the just little mix. fixed just down impacted that for margin the on like a margin cost by quarter the and basis was Gross break FX to about XX points of of

Tycho Peterson

on flush And you delay of Okay, present headwind? couple then flagged clinical and high-end wondering issues can incremental China soft, separately, for X.X to is from just you we heard then about peers? issue? that highlighted, your budget elaborate you of that I'm some a points if then an just X that around for assumption doesn’t And market Chris pressure any in the your out Thanks.

Christopher O'Connell

Yes, let me to try those cover Tycho.

In the X, pilot GPO, year XX a summarize. drugs and a of plus plus coming X the me X we that was grips the grips was in was to X, quickly with really cities. about coming of what It around to market phase ago X XX on just let terms the were

multiple and The of extended set same second more XX round per. winners accounted that drugs widespread, for to provinces, XX

is bidding been bid round and There been third that this are have has completed. The drugs XX XX across provinces.

and being market actually in we've the encouraging I a excited a as Clearly on curve maybe drugs, think drugs more way response a customers cost way I to - a said from on that's that from pragmatic in possibility. purely are there of lot and market a customers that was the is so, encouraged shift from to our in our the more generic underway seen in about prepared quite investment sector, market this. focused the generic in a bend remarks, And my scale while in innovation price-competitive that to

is And other methods, Pharmacopoeia coming well the the regulations or administration which QC should into encourages R&D. more of that couple modernization drug as market as a revised XXXX law Chinese there that, ChP of support including

picture So but take of a we're for it that account, advantage all taking place investing we is are comes. to in that a into growth stability, being necessarily our put back, think bounce assumption I for the and big but sustainable foundations think the not in where future,

I asked correctly. as about the if think you I understood purchases capital high-end well question

we the actually year, improvement of launches. Towards of end a our risk nice product saw spectrometry our mass sales high because new in the

The excited and in SYNAPT a on space, that year. the high category note. position were half I this resolution finished in back introductions, Cyclic product think strong and and is the there about reestablished year we're Those opportunity XS the IMS leading a

also saw lot to which the a we year. activity ramp in But of through continue encouraging the BioAccord

than saw units of BioAccord in we the first QX In in - fact, three sold sold combined. we more quarters we

into new think product assuming we all a in, we're good of a XXXX. about of momentum increment have that in terms point there. our results we So And baking

part on number class That tends of Your our baked of was get a reporting overall, X% last our clinical. be point, lumpy to smaller a pharma. does into on business It business. fairly It's I our trade think revenue. about

detriment to was So pharma. it a slight

think periods, the over well. consistently business there's And priority newborn screening for particularly business company of rolling based clinical and ramping demand three-year we therapeutic could spectrometry pretty going monitoring. to be grown over the for periods, pretty remains time a and more drug We've clinical assays, mass and

business but we lumpier tends on technology a stay to very building - our portfolio it there. be and focused So

Operator

Dan The next UBS. Brennan, from coming is question

Your line is open.

Daniel Brennan

the for Thanks share the about market kind Chris, market thanks. little just molecule of, you than to LC you're a share pain the on wanted loss, you've more trends? conditions versus peers. that questions. the market taking Could anything Great, discuss feeling highlighted I small bit address, obviously where relative

to Thanks. and population pill burgeoning growth, hard us this you over about like, kind the as to this towards, model, sounds pipelines? signpost all here? that importantly, I - generic What market really that's then talked the kind there's improvement And what back distill which but biologic of recover? great, for our drives the are particularly why know will of, count, excitement

Christopher O'Connell

Sure. Yes, Danny. thanks,

about simply pharma being different with we the lot about small different that, has a think a at molecule consistent in sources have that. growth XX% most tougher of market, environment molecule Waters there, is small seen feedback from our such XX% we've that overall, large and a what's market revenue the I as more We're been of of exposure And look overall being exposed. we recently.

and know, a As that's LC business, in QC heavy. mix have that's you pharma is our heavy we unique

of go And can what so and come clearly service and purchasing our to is our majority expecting with We're business. where we stable. cycles, see the underlying within purchasing the share we with very play and see, capital utilization workflows we our installed the see and we our very but base chemistry

is the base. in solid installed this is in in through that basis And digits, which cycle. of stability our underscores has single a chemistry Chemistry pharma, the global by pharma on the remained mid-to-high consistently up very business, way

the our to serve focus some in got there our been and you factors decade as in when advantage unique we simply is so, part to and position ourselves Certainly, of The the and tailwinds, take of market. customers have will, some returns. in continue to pharma with the end of LC the And the yielded India. to middle China decade, if particularly India, headwinds China demand

in tougher been a of has and year the top in noise with the environment. on last in that, litigation fees user And spike generic the market some a U.S. environment

we we're in portfolio, question. your occurs. continued to I very as expanding our our the it market a portfolio excited We've We that and and of fundamentally well. invest rebound it So all attractive when out of understand technology you think and is market LC, point we're think for

Daniel Brennan

new new products the point talked given Okay. and maybe Tycho's it And question modest products. Great, just features of a seems you've time pretty spent one the the you then I just here. to follow-up know number highlighting contribution, Chris. unique on about still

maybe that, we you in should of want success get the math these I a know can't for, behind signpost some So the and as in of little the be flesh what impact don't but towards the larger too weeds out look products? you why new could just kind details, to bit? and far

Christopher O'Connell

said, the back launches, the basis towards Sure. We're of geared half process meaningful in bear development the systems earlier committed the end of while spread a the and in that to began I some spectrometry across came the a to on the BioAccord continuing the year. year were year, fruit year product particularly and was like really by market to update mass larger side these quarter-to-quarter the last

overall simple market I'd the products by face terms, somewhat our the very in new impacted say we the in business. impact that is conditions Dan, of

the where category, see those academic a molecule as the can category. segments governmental and done have prominent You have products better, such impact large more

conditions market And starting I a a impact as at like conditions top we of until should the of more business. point, products. into those But that's the our improve, year prudent new of clearly change assumption the heading market is see bigger the call, the carryover so of see in said, we

taken, pragmatic to be ahead are the we of we're excited have about I impact generally. to but conditions and gains so, for R&D team the the have as think, us stabilize. And And in productivity strategy products, achieving innovation the very, inside new really market a approach very and certainly motivating what's continue - excited making the them forecasting

Operator

Bank The next question is de coming from of Derik America. Bruin,

is open. line Your

Derik de Bruin

morning. good Hi,

Christopher O'Connell

morning. Good

Derik de Bruin

Hey, a couple of questions.

your about the get end $XXX of on million one then, the XXXX. the contribution is is, Andrew and going sort in for the for levered the comment future? the the quarter, million to share M&A, million $XXX X.X you roughly of buyback, the math, given embedded M&A guidance money back in sort on slug sort there. to first activity on is sort revenue the and in to that's first And what's one that of in our the at of year Just or times really general to million And the of $XXX to for you've million full sort sort interrelated looking involved contribution million take deal that first into the table they're to times of $XXX the So out just X potential of by is it the math? thoughts first X.X year, $XXX from times the it by somewhere $XXX for

Christopher O'Connell

Thanks, Derik. I appreciate it.

me so as and comments But excited a Andrew of that and technology. we're then little and to on and Andrew make Alliance, quick buyback program Let super forth, leverage it couple I'm add the happy Sherry well. about a can to about talk targets

and that the sample lot the I've I analyses is go of consistent things next it and as generation ready of of together Andrew cloud from but robotics, in truly One sample on the a in platform heard customers tie most much in way. automate a around software experiments replicate pressure and is also automation and on all point regularly a preparation front to a technology more end to effective

the our have just to of sell instruments, point. We're is big handle part out It's Andrew the in on beneficial that get trying products, to not opportunity, of big modest break but revenue not through a at logic. going the Waters a on we're and which to this fairly also scheme world the pulling will impact

the more very take in had fact, the town our people staying from really opportunity. integration organization sit going advantage down working the that with is and Everybody team as chemistry as the them is the to charge the is Andrew Andrew closely chance people, are I well in and organization within excited. a yesterday leading The be together of I and well to couldn’t and

So along community. more we'll technology we that look move as forward some and of updates to investment with the give sharing

Sherry Buck

we more the follow-up allocation that structure reform, and plan capital as buybacks. been question tax last capital couple against we've over Yes, know, just capital of of came to a started we share on with through optimal is, return and Derik, out of higher you the executing after years working towards

we look as there's going look we at. of So variety a XXXX, at that into factors

from priorities X repurchases that really cetera, leverage we Our in business and a guide would $XXX based year about upon and standpoint, ratio. times the our gave at looking today et performance, of put this low us million our

opportunities. And be times could us M&A kind towards of so goal the factors X.X increase that of could our near-term

the for the So different we at this and full - just the adjustments all there is at where year look and quarter as year. each updates look go set we it our factors, we'll make guide through and we

Christopher O'Connell

hard to forecast as Well, that. you pipeline. know, good a we Derik, Yes, it's do have

selective. very very, are We

as to very is But been have to we'll have just our the what involved do growth, selectively. on our can and it EPS for for terms proactive to it but of in returns and focus what key they of invested situations in time, of they it it those as well a do capital number different can chosen accretion We purposeful over on investments are just continue and take comes, forward as metrics which the move is there.

Operator

coming is Schenkel, from Cowen. question Doug next The

Your line is open.

Douglas Schenkel

outlook then to couple for All for questions ask think questions about right, just good start of margins, want and Thank on to we just I taking the you I morning. want as guys. a growth our clarification XXXX. in

appreciate been times starting the pretty over on the So Waters margin. guys to key bare close argument as peak I'm thesis operating and you're good bad a you pillar on that to sure has margins,

given your address to would into timeframe? this this think XXXX especially And into over for translate a off margin XXXX that you between this, of success four coming the I of I feeds you building planned like argument? how year investments XX% can where operating your in see How bit, investors guidance and measure And would of would and XX%. what

margins? an does Andrew the And of for I this much a really is, how cleanup, part on this is just impact guess specifically, third Alliance have and of operating XXXX

Sherry Buck

about with I'll Andrew the this Alliance. start maybe there Doug, Sherry. is last off Hi, question

dilutive the some our impact We in EPS, gave guide haven't breakout we detail amount a operating expenses it's operating line to operating specifically. and overall done and a our slightly on is margins item there. so all that - There margin modest

of the our margins function XX%, the our of it's you beyond the is variable - a and one about operating year for margin, we our some prior getting margins overall of normalization have think a as in us. line here when XX% things top really costs, But that's headwind we look XXXX growth. at And

operating back and we mid-single to margins as our we above, that's expansion. for or when of being opportunity goal have So higher get digits

And that's that. around kind the factor of so

investing we're investing where our invest pipeline measuring two and say the for line investments in to really growth market I'd product robust capability. far out play some in to to is, areas pipeline we're bringing top that's keep continuing As new as also, continuing and will R&D of making, products the in we're and key commercial our and growth, that

should out again So metrics. force our sales tools top it in as far salesforce.com, growth play as for line

at that's business. in looking investments the making So kind how the of we're we're

Douglas Schenkel

growth, total revenue that's Okay, terms X% you're targeting in growth. of XXXX helpful. And

about talked you a point. new about think given products I

to stable that TA LC to expected return and noted is growth. is to be expected You

think for to that leads you to by cutting to I assumption revenue to recurring going missing X% or embedding just now process of to little than to not range recurring that? Division into here, growth the chase, and do of expect Waters make lower just us we're that sure you are X% be up the get bit I it's an Waters right a you're something up moderating guess, another this elimination, revenue. I want year conclude expecting

Christopher O'Connell

conditions, that, comment let you're and it Doug, apart a see math, and as how comes stable standpoint coming just add better Sherry to of until the as well. take the business benefit certainly plus our piecing me through - said, conditions year nothing saw products. is Yes, we've of I the on can type in we it the the some in new assumption we into really from actually

revenue is really over a stays course of the the about the Actually the where saw in, all performance of year year, XXXX and solid over the revenue we've steady assumption assumption solid revenue same. in some our with some but recurring recurring very improvement been. recurring the year, improvement coming in course with the QX, We consistent

slightly to imply think in we but the we of consistent prior midpoint, maybe assumption the And products. prudent year that's really that new does the saw an at is that down effect with before what and flat instrument

the obviously think and over opportunity very balances outlook that the updating balanced that course looking to a of I risk, year. and forward So

Operator

The next Arias, Dan from question Stifel. is coming

open. is line Your

Daniel Arias

Chris, the the situation. for Thanks following pharma just guys. can morning obviously, a just given XQ budget questions. be BioAccord, the quarter Good choppy spending in up on

up XQ you the momentum expecting quarter-over-quarter factor up the dynamic there? contributions So or be spending product is performance or new that XQ to bigger you placements BioAccord has sequentially? are the to think Do

Christopher O'Connell

for get story Thanks foundational Dan. question. nice course the work we good to as excellent thought a BioAccord, Thanks, to over year, the exposure Yes, Yes. many of as customers the a was lot of it we to money for we and and in sold benefit BioAccords more QX in year budget potential I could some we into than there. a saw QX work QX combined. cycles sold mentioned, Like in we

to on year very to experience, of overall 'XX we're not be - so of move we're stable consistent 'XX prior from modest X%. nice in modest a a purchasing it sort with We're top seen BioAccord. a in regular expecting expecting but on so a quarter QX, or fairly flat relates QX any know line our expecting basis not from certainly dynamic as to QX, you to for but assumptions sequential the positive QX BioAccord quite QX QX, and move sequential guide year we've As a making huge from to necessarily for for we're

Daniel Arias

and look just the if the the new a as Okay. little I'm your than is corporate introduction contributions BioAccord, had pickup? profitability, IMS to there tough maybe just SYNAPT, this benefit at the you product - staying that understand trying a if of as there to of is new bit any just a product be different Sherry, the And one, combined then with but could be Cyclic margin profile average?

Sherry Buck

we products, new those and cases. market, looking we're customer when I to hurdles we're for products as look new have think bringing financial our obviously, demands business at at our

are mass at our the these above And - some little so average. bit I'd or operating margins company of say, particularly the on that products spectrometry a

Daniel Arias

Okay. Thank you so much.

Operator

from coming is question Janney. Knight of next The Paul

is line open. Your

Paul Knight

comment? cadence. that well, to a that seems your you different talk Can is new had more per you introduction Hey, in BioAccord Chris, see Is comments sustainable you else that or more what make statement? that introduction - you obviously there market product sustainable mentioned to be pacing

Christopher O'Connell

thanks. our Paul, significant company platform R&D excited of Yes, really and a strategy. amount function across about the Absolutely, Sure. work in we've the done are

a a last where a at done of that kind in is with the of repeatable and to innovation serve more families more foundation model really as that. work our a example system ton instrument components effectively a architecture of really good move systems of future into a spot produced the instruments for four to of can products can BioAccord years value and that we've from So time of be streams we the one establish cadence systems, next-generation

launched oligonucleotides, will very in in been marketplace well received three this sometime spin core need architecture more new can components and a successfully into BioAccord the system durable So spun applications The which a a year over new are end of capability really ago be the significant again a launch year market. protein, our glycans. carried about year. platform has has original December BioAccord hardware BioAccord by common and is software peptides We routine the of now a application which a the and at time little customers, a firmware bring controller, fundamental the the and that architecture, for basis to new on of and

the to over we coming the routine basis. spend years X a to will And marketplace X can so, but platform a in new to different a versions on needs, X customer BioAccord as a as I've value before, commented on that - as family, stream, is we capability to depending bring XX

You going. can value streams architecture where that may see and to for be our thinking apply systems we certainly same other

largely that, early to begin the which to addition next-generation the had we've is in software Waters platform. and on development Connect, complete And to our process chance commercialization

of a work introductions yield. will what foundational more product lot of a on based move of and cadence towards sustainable about So excited we've systems new a philosophy that the done to more

I think one we have question. more time for

Operator

Beuchaw, from The is question next Wolfe coming Research. Steve

open. is line Your

Stephen Beuchaw

put first And squeezing bit Hi. have wonder if could the of one time more color was questions some of going I TA. here. for quarter we a and you that topline you chemical was around saw with Chris, me the and a the do to for couple to Thanks customers, into half about surprise a it were those in your of had if trends then little ask in the that. how whether the in I with Did XXXX? dynamics for the you, Chris, margin that I Sherry you larger - line expect in expectations play

Christopher O'Connell

the that TA dominated space. revenue companies. expected Sure. polymer consistent. was sold And directionally in the were our into accounts it in and we would large quarter, Steve, some softer chemicals might I of two-thirds as by and than very coming into say, Like trends we've the is imagine, I much chemicals mentioned, large TA got in About you world. but polymers

really before just number greater up for of in because were new We those of among customers trends that up the added softer than that's opened soft a and than at some be ever amount to long we actually end the make customers which year and some the ended smaller actually time earlier creating lot made forecast. saw the exciting ground, spent comment our large that the up those year the can't we a newer, accounts that's I top accounts all even fair but we've of but why new future, big being expected for

I look customers think at big picture, still back step the we great those customers. are and when

share market position team. technologies, very strong in these a and very stable leading We all strong have

ahead, And we to expect so type conditions stabilize. market looking at those the year of

on same line we similar of see do of polymer in we the lot advanced in mentioned, some the of a did as side Waters and the also product some I of in And types those our patterns LCMS characterization accounts. other things

we think we're that. focused So pretty returning I and well, picture the on understand just

thing some is got we've we'll into new that we benefit from to more get the launches exciting this coming other talk we're as product going year year. TA The about

Stephen Beuchaw

hey, we're we trying the ex-currency would added just and operating was, speaking Okay. Andrew in accelerate expense underlying margin if have then to expenses all might a operating Thank it wonder trends, that. you to And by didn't spend much? growth, and you underlying the take year, stab as for I if Sherry, how at, get

for the the us Thank just about is mix wondering dynamics, then Waters and between so what just And mix the who gross remind the can you those much. line TA at you spread business EBIT or business? are

Sherry Buck

operating a just the Yes, back bit peel your maybe little expenses. to question on

without - a it Andrew has year, the of course modest impact. the Andrew Over Alliance

operating our to from look margin operating So really XXXX And and then, could their business, drivers the R&D expense the we as really of the at is drivers capabilities, question? second we're in and the and bigger in expenses are operating and then your investments increase guide variable on related operating expenses margins. both normalization commercial you bigger repeat our making

Christopher O'Connell

I think finishing call might here. we the be

little here we're So a I your live bit And else. over questions. on and well participation me Steve, time think the call. everyone offline there, microphone as But can follow-up not Steve's maybe to for we question thank everybody want let just I and wrap your so is up as certainly

our capital challenging executing purchasing early innovation more the progress. strategy on we excited with remain in are on dynamics our focused Despite and we XXXX,

are R&D, invest purposeful shown have in and While end growth their acquisitions. to growth our confident volatility, for operations, potential in commercial and markets near-term we some continue long-term

to Thank you your our our call, great on XXth, which XXXX have XXXX. entire currently interest I'd like to management look progress continued day. a forward on April team, We and of we in Waters. QX you holding and updating thank for you behalf on during So anticipate our support

Operator

conclude today's This time. may conference. this will at parties All disconnect

Waters (WAT) 4 Feb 202019 Q4 Earnings call transcript